ABVC BioPharma, Inc. (ABVC)

$0.9465

+0.01 (+1.08%)
Rating:
Recommendation:
-
Symbol ABVC
Price $0.9465
Beta 0.488
Volume Avg. 0.09M
Market Cap 30.579M
Shares () -
52 Week Range 0.86-11.69
1y Target Est -
DCF Unlevered ABVC DCF ->
DCF Levered ABVC LDCF ->
ROE -331.64% Strong Sell
ROA -180.74% Strong Sell
Operating Margin -
Debt / Equity 63.36% Buy
P/E -
P/B 3.78 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ABVC news


Mr. Eugene Jiang
Healthcare
Biotechnology
NASDAQ Capital Market

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.